Acrux (ASX:ACR) CEO & Managing Director John Warmbrunn provides an update on the company’s progress in women’s health and its pipeline of topical hormone replacement therapies. Hosted by The Capital Network on 17 August 2026, the investor webinar covers key clinical, regulatory and commercial developments for Acrux. Key topics discussed include:

• Progress towards the clinical and commercial milestones for Acrux’s Female Testosterone MDTS treatment

• The significance of the FDA’s recent Post-End-of-Phase-II response ahead of the planned Phase III trial

• An update on Acrux’s Australian licensing agreement with Gedeon Richter Plc for Lenzetto®, a Menopause Hormone Therapy (MHT) product

• Acrux’s broader strategy to deliver improved treatment options for women’s health

Presenter: John Warmbrunn, CEO & Managing Director, Acrux Hosted by: The Capital Network (TCN) Date: 17 August 2026 Watch the full webinar: https://youtu.be/N2LPQq2WSXE